× ¨ ª Êû É ¤²k÷ /s è / Ö ih m× ¨ ª Êû É ¤²} è / Ö qq o}|...
TRANSCRIPT
s t
q q
u v
km m
k k kk
l
,
l ml l k s m tl s m t
-
l qs+) - t
² n+)0
l q q qG +) , ² k k q k
k ll
² q m k l
l q q qu k
lv
l ov s t
l ml
v s tl m
v l
v s tl s t
s t
l l l l l l
l l
↑
↓
• • 7aRQ : Y ORQ Y FP RYPR 201 4+)) -,-- 31./ /-
n s qtn• m m m• q s t
n s tn• n;a QRYPR C] P PR = [• m
n s t• • k• k• •
s t
a
11r
11
eAH C AH
Sro
lp
tr r11
r mr
ptr
ctr
b v f
y f
AE si n
n
ru
l n• n y
• • n y•
z n+) / sm t ÷
l • ÷m n y• o• n s t
l ÷l
• l l
l l l
l l m s t
l l q
l
n 9 P Y R RYPR Y Wc• s t k p
+ 3 9 X Y X d Y Y Wc• fi
, 3 9 RhRP aRYR Y Wc• ² 3 9 W c Y Wc
• DB D7 n
- 3 9 ORYRe Y Wc• k• s m t•
(
(
(
(
13
r
)) ) ) (
+-) + +) (
新医薬品における費用対効果 12
10100
240 s9;E s 9;E
s t ) +
+
-)
))
+-)
st
s 9;E5 +-) q )) tgs +q ) t50) (s t
s ) ( t
s m tv s t
l • s m q m O7 P t• m• m÷ m÷• m•
l • m m• s9:(:H:t
l • m
v s tl m s t
RaRW r
n
HealthAff(Millwood).2005Jan-Jun;SupplWebExclusives:W5-10-W5-18.
RaRW n qRaRW +n q s b C9 tnRaRW ,n q n 0 yRaRW -n q n
y s k t
PMID:15659453
nq q
0G %1G V K %(+2G SS 0 1 + %(+3G M U .,%+(4G P 3I0 (%5G P 2H4 (.%+6G TQ K ML ( 7G TQ K NL .%, 8G TQ K6 7 %) 9G O TQ + G O T 8H9 )% G P T 4H %(GM P T 2H %G P 4F %.G O T + G P T 1H H ) % .G V K ( %AG P T H H ),%((BG P T JR
A . %.CG (. $ ( $ ,DG %(.,EG K– L O
0 BHCHD ) %. 1
HIE $8.09Billion
$18.8Billion
$31.8Billion
nq k s tq
3 0 3 0
$$V9 v 7
l V9 v 7 L6N 7 (
6 a t7 u (
8 N 44444444444444
)(
N 5 5 5 5 ( (
44444444444444 14 .02 46 e5 7 (( (
HealthAff(Millwood).2005Jan-Jun;SupplWebExclusives:W5-10-W5-18.
k l
R W T FR]a ER +) + :RP4-0n+ ,0 .1 CA :3++.01)1.
+n ; Ei: OR R I d ]Q
-DiabetesWizard-AnnFamMed2011;9:12-21
HbA1c
-DiabetesWizard-AnnFamMed2011;9:12-21
HbA1c
-DiabetesWizard-AnnFamMed2011;9:12-21
HbA1c
-DiabetesWizard-AnnFamMed2011;9:12-21
HbA1c
HbA1c
0.26%(0.06-0.47)
m
:R T:A
97:m9
,/%0)2z )%,)-(
% 0/z-%)0)(
12%/ -(
-,- z+%+.1(
-0%22.z +%+,2(
O7 P ) +/8C: 9
FX V YS
O7 Pz8C: 9
FX V YS
+ :A
s t
-22(
+n ; E: OR R I d ]Q ;AE
HbA1c0.26%↓BPLDL-CSmoking
HbA1cBPLDL-CSmoking
2 DM50
2 M M6 :06 M
524 $:06
ACI L / 0 8O CI IB 9E L AP 2 M M
MO 2 LC . ( )
47 O L (. ( ) ( .
ACI L / LDC CB 9E L AP 2 M M
MO 2 LC . ( )
47 O L ) ( ) ( 3 I I
ACI L (/ 7 AL 2 M ID 9E L AP 2 M M 1 MC 2 MC
MO 2 LC . ( )
47 O L , ( ) ( ( ,HealthServRes.2012Dec;47(6):2137-58
;AE
EMRQALY
$21,690
x#1 /AL 47 #2 /AL 64 #3 /AL 57 #4 /AL 145#5 #1or#2or#3or#4 311
#6 /AL 70,429#7 /AL 514,066#8 ( /THor /AL) 4,337 #9 ( /THor /AL) 507#10#6or#7or#8or#9 568,704
#11#5and#10 16
xL M
( L + ML Mk k k
l
÷ fi s tl oz
l n s t n s tl
l ff s oot
+ s m tl n ÷s tl n s z t
, m q s tl q q
l m q q ql q s m tl s q t
q q
l m
l m
l k ÷
11 AM9:30 11 30 A